BioCentury
ARTICLE | Clinical News

Genasense oblimersen: Updated Phase II data

July 5, 2010 7:00 AM UTC

Updated data from an ongoing, open-label, U.S. Phase II trial in 10 evaluable patients with advanced melanoma showed that 900 mg IV Genasense twice weekly for 4 weeks plus Temodar temozolomide and Abraxane paclitaxel produced 1 complete response, 4 partial responses and 4 cases of stable disease. One patient has yet to be evaluated for response. The trial is expected to enroll an additional 14 patients. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...